Doxycycline eye treatment for persistent wet macular degeneration fluid
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether an “MMP-9 inhibitor” medicine given as doxycycline (a tetracycline-type antibiotic) can reduce persistent leaking and fluid in wet age-related macular degeneration. It may help people whose wet AMD is not fully controlled even after several anti-VEGF injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet age-related macular degeneration affecting the retina (wAMD).
- You’re being treated with anti-VEGF eye injections, and the leaking disease is still active after at least 3 back-to-back injections.
- You still have persistent retinal fluid seen on eye imaging (with or without other fluid) from the wet AMD area.
- You have NOT had bad side effects from tetracycline medicines (the study uses doxycycline).
- You can return for required follow-up visits at about 6 and 9 months.
- You are able to stay on the study injection plan and not need an urgent change to other treatments during the 9 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, EXG202, injected into the eye to treat wet age-related macular degeneration (wAMD). It is for people who have already had some benefit from standard treatments in the past 6 months.
This trial tests a new gene therapy, EXG202, given as an injection into the eye. It aims to see if the treatment is safe and can help slow vision loss from wet AMD, a condition where abnormal blood vessels leak fluid under the retina.
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
This study tests whether a new eye drop medication (SCAI-005) can help people with wet age-related macular degeneration (a serious eye condition affecting central vision in older adults) who have already responded well to regular eye injections. The goal is to see if eye drops might work as an alternative treatment.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.